Business Context and Reporting Period
Company: Daxor Corporation (DXR)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 1997
Headquarters: New York, New York
Daxor Corporation operates in the medical services and technology sector, primarily through its Idant Laboratory division. The Company's core businesses include:
- Blood Volume Analysis: Marketing the BVA-100, a semi-automated instrument for measuring total human blood volume, which received FDA clearance in September 1997.
- Cryobanking: Long-term storage of autologous blood and human semen. The Company holds the only AATB-accredited semen bank in New York State.
Operations are significantly impacted by an ongoing legal dispute with the New York State Department of Health (NYSDOH). Since June 1997, the Company has been blocked from accepting new blood and semen clients, limiting operations to servicing existing storage accounts.
Key Financial Metrics
| Metric | 1997 | 1996 | 1995 |
|---|---|---|---|
| Operating Revenues | $529,737 | $717,308 | $1,864,552 |
| Total Revenues | $2,813,173 | $2,865,835 | $4,748,935 |
| Net Income (Loss) | $(158,853) | $(112,165) | $1,287,115 |
| Net Income Per Share | $(0.03) | $(0.02) | $0.26 |
| Total Assets | $41,322,592 | $37,288,804 | $37,744,621 |
| Shareholders' Equity | $32,917,724 | $31,781,420 | $29,199,180 |
| Working Capital | $32,501,404 | $31,306,579 | $31,598,345 |
| Short-Term Debt | $2,494,639 | $1,636,067 | N/A |
| Market Value of Securities | $40,347,085 | $35,574,526 | N/A |
Note: Total revenues are heavily influenced by dividend income ($2.14M in 1997) and gains on the sale of investments ($144,681 in 1997), rather than core operating revenues.
Material Changes vs. Prior Period
- Operating Revenue Decline: Operating revenues dropped 26% to $529,737 from $717,308 in 1996. This decline is attributed to the inability to accept new clients for blood and semen banking due to the NYSDOH dispute.
- Net Loss: The Company reported a net loss of $158,853 in 1997, widening from a loss of $112,165 in 1996. This contrasts sharply with the $1.29M net income reported in 1995.
- Investment Portfolio Growth: The market value of the Company's securities portfolio increased to $40.35 million (up from $35.57 million in 1996), driven by unrealized gains on utility stocks. This portfolio provides the primary liquidity and offsets operating losses.
- Debt Increase: Short-term debt increased to $2.49 million from $1.64 million, consisting of bank loans and margin debt secured by marketable securities.
- Dividend Payment: Despite the net loss, the Company paid a cash dividend of $0.50 per share ($2.35M total) in 1997.
Outlook, Risks, and Management Commentary
Guidance and Outlook
Management intends to shift focus to the marketing of the Blood Volume Analyzer (BVA-100), estimating a potential market exceeding $100 million annually. The Company plans to market the device via outright sales and lease programs to hospitals. Expansion into a national network of cryo-centers is contingent upon resolving legal disputes and may require additional financing.
Material Risks and Contingencies
- Regulatory Litigation: The Company is engaged in a protracted legal battle with the NYSDOH regarding licensing for its blood and semen banks. A June 1997 Court of Appeals decision reversed a lower court ruling in Daxor's favor, effectively blocking new business in New York. The Company has appealed to the U.S. Supreme Court and filed a $55 million lawsuit in the Court of Claims alleging discriminatory treatment.
- Antitrust Actions: Daxor has filed a $100 million lawsuit against the New York Blood Center and NYSDOH officials alleging antitrust violations and RICO offenses.
- Operational Limitations: Until the legal dispute is resolved, the Company cannot accept new deposits for blood or semen, severely limiting revenue growth in its traditional core business.
- Market Acceptance: Success of the BVA-100 depends on demonstrating cost-effectiveness and overcoming the need for physician education regarding blood volume measurement.
Investor Verification Checklist
- Legal Status: Verify the current status of the appeal to the U.S. Supreme Court and the $55M Court of Claims lawsuit against the NYSDOH.
- Revenue Composition: Confirm the sustainability of dividend income and investment gains, which currently exceed operating revenues.
- BVA-100 Commercialization: Assess the progress of FDA-cleared BVA-100 sales and lease agreements with teaching hospitals.
- Liquidity vs. Debt: Review the ratio of marketable securities ($40.3M) to short-term debt ($2.5M) to ensure margin calls do not force asset liquidation.
- Dividend Sustainability: Evaluate the rationale for paying a $2.35M dividend while reporting a net operating loss and legal uncertainties.